SepMate™-15 (IVD)

Tube for density gradient centrifugation for in vitro diagnostic (IVD) applications

Try SepMate™-15 (IVD) tubes for density gradient centrifugation in your IVD applications. Request a Sample

SepMate™-15 (IVD)

Tube for density gradient centrifugation for in vitro diagnostic (IVD) applications

From: 460 USD
Catalog #
(Select a product)
Tube for density gradient centrifugation for in vitro diagnostic (IVD) applications
Add to Wish List

Product Advantages

  • Eliminates the need for carefully layering blood over the density gradient medium (e.g. Lymphoprep™, etc.)

  • Reduces total centrifuge time to 10 minutes with the brake on for fresh samples

  • Allows fast and easy harvesting of the isolated mononuclear cells by simply pouring off the supernatant

  • Can be combined with RosetteSep™ enrichment cocktails to isolate specific cell types in just 30 minutes

What's Included

  • SepMate™-15 (IVD), 100 Tubes (Catalog #85415)
    • Dispenser box containing 4 bags, 25 Tubes/Bag
  • SepMate™-15 (IVD), 500 Tubes (Catalog #85420)
    • Dispenser box containing 4 bags, 25 Tubes/Bag (Catalog #85415) x 5
Products for Your Protocol

What Our Scientist Says

Traditional isolation of PBMCs requires careful layering of blood onto density gradient media prior to centrifugation. We developed SepMate™ to simplify this process, so anyone can isolate PBMCs with a simple pour while maintaining consistency across samples.

Peter MorinTechnical Scientist
Peter Morin, Technical Scientist


Simplify peripheral blood mononuclear cell (PBMC) isolation by incorporating SepMate™ into your density gradient centrifugation step.

SepMate™ tubes contain an insert that creates a barrier between the density gradient medium and blood, thus eliminating the need for careful blood layering and allowing mononuclear cells to be easily harvested with a simple pour. This product can be used with RosetteSep™ to isolate specific immune cell subsets.

SepMate™ is manufactured under cGMP and registered as an In Vitro Diagnostic (IVD) device in Australia, Canada, Europe, and the USA. In China, SepMate™ is considered a nonmedical device by the China Food and Drug Administration (CFDA) and should be used as general lab equipment. The end user is responsible for determining whether the product is suitable for their specific application.

Browse our Frequently Asked Questions (FAQs) on SepMate™.
Polypropylene tube containing an insert
Centrifugation Tubes
Cell Type
B Cells, Dendritic Cells, Monocytes, Mononuclear Cells, NK Cells, T Cells, T Cells, CD4+, T Cells, CD8+, T Cells, Other Subsets, T Cells, Regulatory
Sample Source
Bone Marrow, Whole Blood
Selection Method
Cell Isolation, In Vitro Diagnostic
Area of Interest
Chimerism, HLA, Immunology

Data Figures

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 1. Recovery of mononuclear cells (MNCs) from peripheral blood using SepMate™-50 versus standard density gradient centrifiguation.

Recovery of MNCs from fresh and 48-hour post blood draw enriched by density gradient centrifugation with SepMate™ (purple) or without (grey). There was no significant difference in the recovery of MNCS with and without SepMate™.

PBMC recovery from fresh whole blood using SepMate™-50 versus standard density gradient centrifugation. Graph also shows PBMC recovery from a 48 hour-old sample using SepMate™. n in each group = 7

Figure 2. Human CD4+ T Cell Isolation using SepMate™-50 and RosetteSep™ Human CD4+ T Cell Enrichment Cocktail

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Catalog #
85415, 85420
Lot #

Resources and Publications

Publications (30)

A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus. R. Ganugula et al. Science advances 2020 jun


Cyclosporine A (CsA) is a powerful immunosuppressant, but it is an ineffective stand-alone treatment for systemic lupus erythematosus (SLE) due to poor target tissue distribution and renal toxicity. We hypothesized that CD71 (transferrin receptor 1)-directed delivery of CsA to the lymphatic system would improve SLE outcomes in a murine model. We synthesized biodegradable, ligand-conjugated nanoparticles [P2Ns-gambogic acid (GA)] targeting CD71. GA conjugation substantially increased nanoparticle association with CD3+ or CD20+ lymphocytes and with intestinal lymphoid tissues. In orally dosed MRL-lpr mice, P2Ns-GA-encapsulated CsA increased lymphatic drug delivery 4- to 18-fold over the ligand-free formulation and a commercial CsA capsule, respectively. Improved lymphatic bioavailability of CsA was paralleled by normalization of anti-double-stranded DNA immunoglobulin G titer, plasma cytokines, and glomerulonephritis. Thus, this study demonstrates the translational potential of nanoparticles that enhance the targeting of lymphatic tissues, transforming CsA into a potent single therapeutic for SLE.
Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma. W. Fu et al. Frontiers in immunology 2020


The Glioblastoma (GBM) immune microenvironment plays a critical role in tumor development, progression, and prognosis. A comprehensive understanding of the intricate milieu and its interactions remains unclear, and single-cell analysis is crucially needed. Leveraging mass cytometry (CyTOF), we analyzed immunocytes from 13 initial and three recurrent GBM samples and their matched peripheral blood mononuclear cells (pPBMCs). Using a panel of 30 markers, we provide a high-dimensional view of the complex GBM immune microenvironment. Hematoxylin and eosin staining and polychromatic immunofluorescence were used for verification of the key findings. In the initial and recurrent GBMs, glioma-associated microglia/macrophages (GAMs) constituted 59.05 and 27.87{\%} of the immunocytes, respectively; programmed cell death-ligand 1 (PD-L1), T cell immunoglobulin domain and mucin domain-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), interleukin-10 (IL-10) and transforming growth factor-$\beta$ (TGF$\beta$) demonstrated different expression levels in the GAMs among the patients. GAMs could be subdivided into different subgroups with different phenotypes. Both the exhausted T cell and regulatory T (Treg) cell percentages were significantly higher in tumors than in pPBMCs. The natural killer (NK) cells that infiltrated into the tumor lesions expressed higher levels of CXC chemokine receptor 3 (CXCR3), as these cells expressed lower levels of interferon-$\gamma$ (IFN$\gamma$). The immune microenvironment in the initial and recurrent GBMs displayed similar suppressive changes. Our study confirmed that GAMs, as the dominant infiltrating immunocytes, present great inter- and intra-tumoral heterogeneity and that GAMs, increased exhausted T cells, infiltrating Tregs, and nonfunctional NK cells contribute to local immune suppressive characteristics. Recurrent GBMs share similar immune signatures with the initial GBMs except the proportion of GAMs decreases.
A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1 P. Tao et al. Nature 2020


Activation of RIPK1 controls TNF-mediated apoptosis, necroptosis and inflammatory pathways1. Cleavage of human and mouse RIPK1 after residues D324 and D325, respectively, by caspase-8 separates the RIPK1 kinase domain from the intermediate and death domains. The D325A mutation in mouse RIPK1 leads to embryonic lethality during mouse development2,3. However, the functional importance of blocking caspase-8-mediated cleavage of RIPK1 on RIPK1 activation in humans is unknown. Here we identify two families with variants in RIPK1 (D324V and D324H) that lead to distinct symptoms of recurrent fevers and lymphadenopathy in an autosomal-dominant manner. Impaired cleavage of RIPK1 D324 variants by caspase-8 sensitized patients' peripheral blood mononuclear cells to RIPK1 activation, apoptosis and necroptosis induced by TNF. The patients showed strong RIPK1-dependent activation of inflammatory signalling pathways and overproduction of inflammatory cytokines and chemokines compared with unaffected controls. Furthermore, we show that expression of the RIPK1 mutants D325V or D325H in mouse embryonic fibroblasts confers not only increased sensitivity to RIPK1 activation-mediated apoptosis and necroptosis, but also induction of pro-inflammatory cytokines such as IL-6 and TNF. By contrast, patient-derived fibroblasts showed reduced expression of RIPK1 and downregulated production of reactive oxygen species, resulting in resistance to necroptosis and ferroptosis. Together, these data suggest that human non-cleavable RIPK1 variants promote activation of RIPK1, and lead to an autoinflammatory disease characterized by hypersensitivity to apoptosis and necroptosis and increased inflammatory response in peripheral blood mononuclear cells, as well as a compensatory mechanism to protect against several pro-death stimuli in fibroblasts.
Try SepMate™-15 (IVD) tubes for density gradient centrifugation in your IVD applications. Request a Sample